Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 4, 2013, Pages 872-875

  Takano, Masashi ^a,b   Ikeda, Yuji ^b,d   Kudoh, Kazuya ^b,c   Kita, Tsunekazu ^b,e   Sasaki, Naoki ^a,b   Kikuchi, Yoshihiro ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

^c National Hospital Organization Saitama Hospital   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bevacizumab; Clear cell carcinoma; Oxaliplatin; Recurrent ovarian cancer; Trabectedin

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TEMSIROLIMUS; TRABECTEDIN;

ADULT; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CLEAR CELL CARCINOMA; CONSTIPATION; EPISTAXIS; FATIGUE; FEMALE; HUMAN; INFORMED CONSENT; JAPANESE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN PAIN; TREATMENT DURATION; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; REMISSION INDUCTION; TETRAHYDROISOQUINOLINES;

EID: 84880025072     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.02047.x     Document Type: Article

References (17)

1. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007; 105: 404-408.
2. Takano M, Sugiyama T, YaegashiNet al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 2008; 18: 937-942.
3. Yoshino K, Enomoto T, Fujita M et al. Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: A single-institution experience for a series of 20 patients. Int J Clin Oncol 2011; Epub ahead of print.
4. Takano M, Goto T, Kato M, Sasaki N, Miyamoto M, Furuya K. Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary. Int J Clin Oncol 2012; Epub ahead of print.
5. Takano M, Kikuchi Y, Kudoh K et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases. Int J Clin Oncol 2011; 16: 605-609.
6. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
7. D'Incalci M, Colombo T, Ubezio P et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39: 1920-1926.
8. Dieras V, Bougnoux P, Petit T et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann Oncol 2002; 13: 258-266.
9. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
10. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171.
11. Kudoh K, Takano M, Kouta H et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 2011; 122: 233-237.
12. Klement G, Huang P, Mayer B et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002; 8: 221-232.
13. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: A potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009; 14: 1242-1251.
14. Mabuchi S, Hisamatsu T, Kawase C et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res 2011; 17: 4462-4473.
15. Ikeda Y, Kikuchi Y, Takano M et al. Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer. J Clin Oncol 2012; 30: abstr 5037.
16. Horowitz NS, Penson RT, Duda DG et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent Müllerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig 2011; 4: 26-33.
17. Forouzesh B, Hidalgo M, Chu Q et al. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res 2009; 15: 3591-3599.